Danish vaccine company will run studies in Africa while on the hunt for capital in Europe and USA
Biotech company Minervax is preparing phase II studies of its streptococcus infection vaccine in Uganda and South Africa and trying to raise money for studies in USA and Europe.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY CATHERINE BRETT
Minervax is based at the Cobis building in Copenhagen, but before long, the company will be making its mark in Uganda and South Africa.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Minervax receives million-funding for new trial
For abonnenter
EU commission chair speaks personally to vaccine company
For abonnenter
